Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer.
Ontology highlight
ABSTRACT: Prostate cancer is the most diagnosed malignancy in men in the United States and the second leading cause of cancer-related death. For localized disease, radiation therapy is a standard treatment that is often curative. For metastatic disease, radiation therapy has been primarily used for palliation, however, several newer systemic radiation therapies have been demonstrated to significantly improve patient outcomes and improve survival. In particular, several targeted radionuclide therapies have been approved for the treatment of advanced-stage cancer, including strontium-89, samarium-153, and radium-223 for bone-metastatic disease, and lutetium-177-labeled PSMA-617 for patients with prostate-specific membrane antigen (PSMA)-expressing metastatic castration-resistant prostate cancer (mCRPC
SUBMITTER: Muralidhar A
PROVIDER: S-EPMC9863141 | biostudies-literature | 2023 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA